Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in SwedenCost-effectiveness of statin treatment strategies

Current Medical Research and Opinion

Volumn 26, Issue 2, 2010, Pages 389-396

  Martikainen, Janne A ^a,b   Soini, Erkki ^a   Paulsson, Thomas ^c  

^a Esior Oy   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Coronary heart disease; Cost effectiveness; Statin; Treatment target

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; GOAL ATTAINMENT; HIGH RISK PATIENT; HUMAN; MEDICAL LITERATURE; SWEDEN;

ALGORITHMS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTH PLANNING GUIDELINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MODELS, ECONOMETRIC; RETROSPECTIVE STUDIES; SWEDEN; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 74549139157     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903498653     Document Type: Article

References (25)

1. Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006; 27:1610-1619 (Pubitemid 43954923)
2. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. The Lancet 2005; 366:1267-1278
3. Law M, Wald N, Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-1431
4. Svilaas A, Strandberg T, Eriksson M, et al. Lipid lowering patterns and goal attainment in Nordic patients with hyperlipidemia. Scand Cardiovasc J 2008;42:279-287
5. Lindgren P, Borgström F, Stalhammar J, et al. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiov Prev R 2005;12:530-534
6. Carlsson A, Borgström F, Stalhammar J, et al. Cost of care for patients treated with lipid-lowering drugs. Pharmacoeconomics 2004;22(Suppl. 3): 25-35
7. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical prevention. Eur J Cardiov Prev R 2007;14(Suppl. 2):S1-113
8. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-160
9. Peura P, Martikainen J, Soini E, et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin 2008;24:1825-1834
10. Lindgren P, Buxton M, Kahan T, et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Eur J Cardiov Prev R 2005;12:29-36
11. Johannesson M, Jö nsson B, Kjekshus J, et al. Cost effectiveness of simvas-tatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997;336:332-336
12. Benner J, Smith T, Klingman D, et al. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health 2005;8:618-628
13. Palmer S, Brady A, Ratcliffe A. The cost-effectiveness of a new statin (rosu-vastatin) in the UK NHS. Int J Clin Pract 2003;57:792-800
14. Peura P, Martikainen J, Hallinen T, et al. Statiinien teho ja kustannusvaikut-tavuus [Cost-effectiveness of statins in reaching LDL cholesterol levels defined in Current Care Guidelines]. Fin Med J 2007;42:3899-3905
15. Lä kemedelsfö rma° nsnä mnden (LFN). Price database (pharmaceuticals), 2008
16. Sö dra Regionva° rdsnä mnden. Regionala priser och ersättningar för södra sjukva°rdsregionen 2008 [http://www.skane.se/upload/Webbplatser/ Sodra%20regionvardsnamnden/prislista/ 2008/helaprislistan2008.pdf. Last accessed 7 December 2007]
17. Law MR, Wald N, Thompson S. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-372 (Pubitemid 24078498)
18. Jowett S, Stirling B, Mahé I, et al. A multinational investigation of time and traveling costs in attending anticoagulation clinics. Value Health 2008;11:207-211
19. Werner P, Brun J. POST (Prescription of statin study)-en model för kvali-tetsuppfö ljning av lipidsänkande lä kemedel i sjukva° rden. Medicinskt Forum 2006;2:22-25
20. Briggs A, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastro-esophageal reflux disease. Med Decis Making 2002;22:290-308
21. Drummond M, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd Edn. New York: Oxford University Press, 2005
22. Barton G, Briggs A, Fenwick E. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curves (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfect information (EVPI). Value Health 2008;11:886-897
23. American Diabetes Association (ADA). Standards of medical care in diabetes. Diabetes Care 2005;28:S4-36
24. Silva M, Swanson A, Gandhi P, et al. Statin-related adverse events: a meta-analysis. Clin Ther 2006;28:26-35
25. Heintjes E, Hirsch M, van der Linden M, et al. LDL-C reductions and goal attainment among naïve statin users in the Netherlands: real life results. Curr Med Res Opin 2008;8:2241-2250